

**6<sup>TH</sup> ANNUAL NATIONAL CONGRESS ON  
HEALTH CARE COMPLIANCE**

**February 6-7, 2003  
Washington, D.C.**

**COMPLIANCE RISKS FOR PHARMACEUTICAL COMPANIES**

**Lynn Shapiro Snyder, Esq.**  
Epstein Becker & Green, P.C.  
Washington, D.C. 20037  
[lsnyder@ebglaw.com](mailto:lsnyder@ebglaw.com)  
202-861-1806

# COMPLIANCE RISKS FOR PHARMACEUTICAL COMPANIES

By

**Lynn Shapiro Snyder, Esq.**  
Epstein Becker & Green, P.C.  
Washington, D.C. 20037  
lsnyder@ebglaw.com  
202-861-1806

## **I. The OIG's List of Compliance Risks for Pharmaceutical Companies**

- A. See, "The OIG's Draft Compliance Guidance for Pharmaceutical Manufacturers: One More Compliance 'Script' for the Health Care Industry" co-authored with Wendy Goldstein, Partner, New York office.
- B. See, Relevant Excerpts from the OIG 2003 Work Plan

## **II. A Closer Look At Marketing**

- A. See, "Pharmaceutical Sales and Marketing Compliance: Are You Afraid to Look Under That Rock? – Twelve Key Tips To Achieve Effective Training to Pharma Sales and Marketing Personnel", co-authored with Wendy Goldstein, Partner, New York office.

## **III. Other Compliance Risks Not Otherwise Mentioned**

- A. See Eli Lilly Privacy Complaint Consent Order with the Federal Trade Commission
- B. Pharma Settlement Chart maintained by EBG

## **IV. Compliance Program Effectiveness**

- A. See, "Defining, Quantifying, and Measuring Effectiveness"